Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.39 +4.8%	$1.96	$1.33 ▼ $3.58	$112.59M	0.74	105,895 shs	193,346 shs
CRBP Corbus Pharmaceuticals	$9.79 +0.9%	$8.59	$4.64 ▼ $61.72	$119.98M	3.2	107,908 shs	157,942 shs
MDCX Medicus Pharma	$2.22 -9.4%	$2.67	$1.80 ▼ $8.94	$39.55M	N/A	421,091 shs	590,547 shs
SKYE Skye Bioscience	$3.29 -7.3%	$3.68	$1.14 ▼ $7.47	$101.95M	2.21	313,795 shs	488,202 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	0.00%	+41.42%	+20.10%	+31.32%	-5.16%
CRBP Corbus Pharmaceuticals	0.00%	+5.84%	+8.66%	+32.30%	-84.09%
MDCX Medicus Pharma	0.00%	+13.27%	-26.49%	-69.55%	+221,999,900.00%
SKYE Skye Bioscience	0.00%	-6.27%	-17.96%	+73.16%	-40.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership
ADAG Adagene	3.0468 of 5 stars	3.5	5.0	0.0	2.6	1.7
CRBP Corbus Pharmaceuticals	4.324 of 5 stars	3.6	3.0	4.7	2.8	2.5
MDCX Medicus Pharma	1.8743 of 5 stars	3.8	0.0	0.0	2.2	0.8
SKYE Skye Bioscience	1.6914 of 5 stars	3.6	2.0	0.0	1.6	0.8

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	3.00	Buy	$7.00	192.89% Upside
CRBP Corbus Pharmaceuticals	3.10	Buy	$49.00	400.51% Upside
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	958.56% Upside
SKYE Skye Bioscience	3.14	Buy	$15.50	371.12% Upside

Current Analyst Ratings Breakdown

Latest MDCX, CRBP, SKYE, and ADAG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
8/15/2025	ADAG Adagene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
8/15/2025	SKYE Skye Bioscience	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2025	SKYE Skye Bioscience	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
8/13/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
8/6/2025	ADAG Adagene	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	ADAG Adagene	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
8/6/2025	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$56.00 ➝ $53.00
7/30/2025	CRBP Corbus Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$28.00
7/12/2025	CRBP Corbus Pharmaceuticals	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$100K	1,125.93	N/A	N/A	$1.14 per share	2.10
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$11.69 per share	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.29 per share	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$2.25 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$33.42M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	-$40.21M	-$4.76	N/A	N/A	N/A	-43.65%	-39.62%	11/6/2025 (Estimated)
MDCX Medicus Pharma	-$11.16M	-$1.34	N/A	N/A	N/A	-549.30%	-228.06%	N/A
SKYE Skye Bioscience	-$26.57M	-$1.06	N/A	N/A	N/A	-76.03%	-69.20%	N/A

Latest MDCX, CRBP, SKYE, and ADAG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	MDCX Medicus Pharma	-$0.39	-$0.43	-$0.04	-$0.43	N/A	N/A
8/7/2025	Q2 2025	SKYE Skye Bioscience	-$0.34	-$0.44	-$0.10	-$0.44	N/A	N/A
8/5/2025	Q2 2025	CRBP Corbus Pharmaceuticals	-$1.55	-$1.44	+$0.11	-$1.44	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	2.29	2.30
CRBP Corbus Pharmaceuticals	N/A	9.21	9.21
MDCX Medicus Pharma	N/A	1.29	1.29
SKYE Skye Bioscience	N/A	6.09	6.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
CRBP Corbus Pharmaceuticals	64.64%
MDCX Medicus Pharma	N/A
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
CRBP Corbus Pharmaceuticals	4.00%
MDCX Medicus Pharma	11.20%
SKYE Skye Bioscience	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	47.11 million	37.12 million	Not Optionable
CRBP Corbus Pharmaceuticals	40	12.26 million	11.77 million	Optionable
MDCX Medicus Pharma	N/A	17.82 million	15.82 million	N/A
SKYE Skye Bioscience	11	30.99 million	30.06 million	Optionable

MDCX, CRBP, SKYE, and ADAG Headlines

Recent News About These Companies

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by Analysts

August 24 at 2:57 AM | marketbeat.com

Skye Bioscience (NASDAQ:SKYE) Major Shareholder 5Am Partners Vii, Llc Sells 60,956 Shares

August 23 at 9:18 AM | insidertrades.com

Skye Bioscience, Inc. to Present at Multiple Investment and Medical Conferences in September 2025

August 21 at 7:51 AM | quiverquant.comQ

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

August 21 at 7:00 AM | globenewswire.com

Skye Bioscience (NASDAQ:SKYE) Upgraded by Evercore ISI to Strong-Buy Rating

August 18, 2025 | marketbeat.com

Skye Bioscience (NASDAQ:SKYE) Raised to "Strong-Buy" at Evercore ISI

August 17, 2025 | americanbankingnews.com

Evercore ISI Group Initiates Coverage of Skye Bioscience (SKYE) with Outperform Recommendation

August 16, 2025 | msn.com

Evercore starts Skye Bioscience at Outperform on nimacimab potential

August 14, 2025 | msn.com

Skye Bioscience initiated with an Outperform at Evercore ISI

August 14, 2025 | msn.com

Skye Bioscience, Inc. (NASDAQ:SKYE) is Altium Capital Management LLC's 9th Largest Position

August 14, 2025 | marketbeat.com

Skye Bioscience Earnings Call: Positive Outlook Amid Challenges

August 13, 2025 | msn.com

Skye Bioscience signals late Q3/early Q4 top-line Phase IIa results as nimacimab advances obesity treatment platform

August 9, 2025 | msn.com

Skye Bioscience Inc (SKYE) Q2 2025 Earnings Call Highlights: Promising Trial Progress Amid ...

August 9, 2025 | finance.yahoo.com

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

August 7, 2025 | globenewswire.com

We Think Skye Bioscience (NASDAQ:SKYE) Needs To Drive Business Growth Carefully

August 6, 2025 | finance.yahoo.com

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

July 30, 2025 | globenewswire.com

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by Analysts

July 28, 2025 | marketbeat.com

Skye Bioscience (NASDAQ:SKYE) Shares Down 8% - What's Next?

July 25, 2025 | marketbeat.com

SKYE Stock Price Quote | Morningstar

July 11, 2025 | morningstar.comM

Skye Bioscience, Inc. (SKYE) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX, CRBP, SKYE, and ADAG Company Descriptions

Adagene NASDAQ:ADAG

$2.39 +0.11 (+4.82%)

Closing price 08/22/2025 03:57 PM Eastern

Extended Trading

$2.42 +0.02 (+1.05%)

As of 08/22/2025 06:54 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Corbus Pharmaceuticals NASDAQ:CRBP

$9.79 +0.09 (+0.93%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.75 -0.04 (-0.40%)

As of 08/22/2025 07:56 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Medicus Pharma NASDAQ:MDCX

$2.22 -0.23 (-9.39%)

As of 08/22/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Skye Bioscience NASDAQ:SKYE

$3.29 -0.26 (-7.32%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.39 +0.10 (+3.04%)

As of 08/22/2025 07:57 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time